Welcome to our dedicated page for Stepan SEC filings (Ticker: SCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stepan Company filings document the regulatory record for a specialty and intermediate chemicals manufacturer whose common stock trades on the New York Stock Exchange under symbol SCL. Its 8-K filings report operating results, dividend declarations, material-event disclosures, capital-structure information and exit or disposal activities tied to manufacturing and efficiency initiatives.
Stepan proxy and annual-meeting filings cover director elections, advisory compensation votes, auditor ratification, executive compensation governance and benefit-plan matters. The filing record also includes disclosure on restructuring charges, asset write-downs, decommissioning costs and other governance or financial matters reported through current reports and proxy materials.
STEPAN CO director Jan Stern Reed received a grant of 2,566 shares of Common Stock on May 8, 2026. The award is recorded at $52.61 per share and is classified as a grant, award, or other acquisition rather than an open-market purchase. Following this equity award, Reed directly holds 16,477 shares of STEPAN CO Common Stock.
Lewis Susan reported acquisition or exercise transactions in this Form 4 filing.
Stepan Co director Susan Lewis received a compensation-related grant of 2,566 shares of Common Stock on May 8, 2026, at a price of $52.61 per share. Following this award, her directly held stake increased to 6,962 shares of Stepan Co common stock.
STEPAN CO director Joaquin Delgado received a grant of 2,566 shares of Common Stock on May 8, 2026. The award is recorded at $52.61 per share, reflecting a compensation-related acquisition rather than an open-market purchase. Following this grant, Delgado directly holds 18,637 shares of Stepan common stock.
Burgess Lorinda reported acquisition or exercise transactions in this Form 4 filing.
STEPAN CO director Lorinda Burgess received a grant of 2,566 shares of Common Stock on May 8, 2026. The award was recorded at a price of $52.61 per share, reflecting compensation rather than an open-market purchase. Following this grant, she directly holds 5,900 Common Stock shares in total.
STEPAN CO director Randall S. Dearth received a grant of 2,566 shares of Common Stock on May 8. The shares were awarded at a reference price of $52.61 per share and are characterized as a grant, award, or other acquisition rather than an open-market purchase. Following this compensation-related award, his direct holdings increased to 16,672 shares of STEPAN CO Common Stock, indicating a routine adjustment to his equity position as a board member.
Stepan Company reported a sharp swing to a loss in Q1 2026, driven by a major restructuring under Project Catalyst. Net sales rose slightly to $604.5 million, but the company recorded a net loss of $41.4 million, or $(1.81) per diluted share, versus earnings of $0.86 a year earlier.
The loss reflects a $65.4 million pre-tax business restructuring charge tied to shutting down the Fieldsboro, New Jersey site and decommissioning assets at the Millsdale, Illinois and Stalybridge, U.K. facilities. Adjusted net income was $10.3 million, or $0.45 per diluted share, down from $0.84.
Surfactants remained the largest segment, generating $453.7 million of net sales but lower operating income, while Polymers earned slightly more despite an 11% sales decline. Specialty Products grew sales 24% but saw lower profit due to product mix and higher raw material costs. Operating cash flow improved to $16.9 million, and Stepan ended the quarter with $140.8 million in cash and $651.7 million of total debt.
Stepan Company executive Robert Joseph Haire reported routine equity compensation activity involving restricted stock units (RSUs). On May 1, 2026, 550 RSUs were settled into the same number of common shares, consistent with the award terms that each RSU converts into one share.
To cover associated tax liabilities on the RSU vesting, 162 common shares were withheld, a non‑market disposition that does not represent an open‑market sale. After these transactions, Haire directly holds approximately 3,959.765 shares of Stepan common stock.
Stepan Company reported voting results from its April 28, 2026 annual stockholder meeting. A quorum was present, with 19,939,848 common shares represented in person or by proxy.
Stockholders elected three directors to terms expiring in 2029. Joaquin Delgado received 17,708,824 votes for and 574,142 against, Corning F. Painter received 18,083,634 for and 199,377 against, and F. Quinn Stepan, Jr. received 17,761,172 for and 528,911 against, with additional abstentions and broker non-votes on each nominee.
Stockholders approved, on an advisory basis, the compensation of Stepan’s named executive officers, with 17,000,565 votes for, 1,233,415 against, and 67,131 abstentions. They also ratified the appointment of Deloitte & Touche LLP as Stepan’s independent registered public accounting firm for 2026, with 19,630,780 votes for, 289,370 against, and 19,698 abstentions.
Vanguard Portfolio Management reports beneficial ownership of 1,372,514 shares of Stepan Co common stock, representing 6.04% of the class as reported in a Schedule 13G. The filing shows sole voting power 13,661 and sole dispositive power 1,372,514, with the position tied to Vanguard-managed funds and accounts.
Stepan Company reported a first quarter 2026 net loss of $41.4 million, or $(1.81) per diluted share, compared with net income of $19.7 million a year earlier. The loss was driven by a previously announced pre-tax business restructuring charge of $65.4 million related to closing the Fieldsboro, NJ site and decommissioning select assets in Illinois and the UK.
Excluding deferred compensation, environmental items and restructuring, adjusted net income was $10.3 million, down 47%, and adjusted earnings per diluted share were $0.45 versus $0.84. Net sales rose 2% to $604.5 million, while consolidated adjusted EBITDA fell 14% to $49.6 million as weaker Surfactants performance outweighed stronger Polymers results.
Surfactants net sales increased 5% to $453.7 million, but adjusted EBITDA declined 15%. Polymers net sales declined 11% to $130.0 million, while adjusted EBITDA grew 8% on margin improvement. Specialty Products net sales rose 24% to $20.8 million, with adjusted EBITDA down 11%. Stepan generated operating cash flow of $16.9 million and negative free cash flow of $14.0 million after $30.9 million of capital expenditures.
The company also entered into an agreement to sell a parcel of land near its Millsdale site for $30 million, subject to customary closing conditions. Separately, the Board declared a quarterly cash dividend of $0.395 per share, payable on June 15, 2026 to shareholders of record on June 1, 2026.
Stepan Company reported a first quarter 2026 net loss of $41.4 million, or $(1.81) per diluted share, compared with net income of $19.7 million a year earlier. The loss was driven by a previously announced pre-tax business restructuring charge of $65.4 million related to closing the Fieldsboro, NJ site and decommissioning select assets in Illinois and the UK.
Excluding deferred compensation, environmental items and restructuring, adjusted net income was $10.3 million, down 47%, and adjusted earnings per diluted share were $0.45 versus $0.84. Net sales rose 2% to $604.5 million, while consolidated adjusted EBITDA fell 14% to $49.6 million as weaker Surfactants performance outweighed stronger Polymers results.
Surfactants net sales increased 5% to $453.7 million, but adjusted EBITDA declined 15%. Polymers net sales declined 11% to $130.0 million, while adjusted EBITDA grew 8% on margin improvement. Specialty Products net sales rose 24% to $20.8 million, with adjusted EBITDA down 11%. Stepan generated operating cash flow of $16.9 million and negative free cash flow of $14.0 million after $30.9 million of capital expenditures.
The company also entered into an agreement to sell a parcel of land near its Millsdale site for $30 million, subject to customary closing conditions. Separately, the Board declared a quarterly cash dividend of $0.395 per share, payable on June 15, 2026 to shareholders of record on June 1, 2026.